tbuckley/cabot-search huggingface dataset:
P17-2 Three cases of PanIN found in dilated pancreatic ducts
Authors: Hiroyuki Kato, Yukio Asano, Masahiro Ito, Norihiko Kawabe, Satoshi Arakawa, Masahiro Shimura, Daisuke Koike, Chihiro Hayashi, Takayuki Ochi, Kenshiro Kamio, Toki Kawai, Hironobu Yasuoka, Takahiko Higashiguchi, Akihiko Horoguchi
Journal: Annals of Oncology (2022)
P19-4 A cross-sectional study and awareness of breast self-examination of Bangladeshi women at Dhaka Medical College Hospital
Authors: Farzana Sultana, Sharika Marjan, Md. Shariful Islam, A.K.M. Nazrul Islam, Nur-E Alam, A.K.M. Mohiuddin, Mst. Mahmuda Khatun
Journal: Annals of Oncology (2022)
Securing the chest tube: in search of the elusive solution
Authors: Srinivas R. Mummadi, José M. Porcel
Journal: European Respiratory Journal (2022)

Chest tubes are frequently indicated for removing accumulated air or fluid from the pleural space due to a variety of conditions, such as pneumothorax, empyema, haemothorax or malignant pleural effusions for which a bedside pleurodesis procedure is planned [1]. Small-bore chest tubes (SBCT), defined as those having an outer diameter of 14 Fr or less, are recommended as a first-line approach in most situations, with the possible exception of haemothoraces. They are ordinarily placed by utilising the Seldinger technique and then secured after insertion to prevent accidental removal [2]. In addition to suturing small-bore chest tubes, integrated devices such as inflatable balloons can also be used to further prevent the risk of tube dislodgment <https://bit.ly/3HPrzFf>
Pathologically triggered in situ aggregation of nanoparticles for inflammation-targeting amplification and therapeutic potentiation
Authors: Qiang Nie, Chenwen Li, Yu Wang, Yi Hu, Wendan Pu, Qixiong Zhang, Jiajun Cai, Yongyao Lin, Gang Li, Chenping Wang, Lanlan Li, Yin Dou, Jianxiang Zhang
Journal: Acta Pharmaceutica Sinica B (2022)

Uncontrolled and persistent inflammation is closely related to numerous acute and chronic diseases. However, effective targeting delivery systems remain to be developed for precision therapy of inflammatory diseases. Herein we report a novel strategy for engineering inflammation-accumulation nanoparticles via phenolic functionalization. Different phenol-functionalized nanoparticles were first developed, which can undergo in situ aggregation upon triggering by the inflammatory/oxidative microenvironment. Phenolic compound-decorated poly (lactide-co-glycolide) nanoparticles, in particular tyramine (Tyr)-coated nanoparticles, showed significantly enhanced accumulation at inflammatory sites in mouse models of colitis, acute liver injury, and acute lung injury, mainly resulting from in situ cross-linking and tissue anchoring of nanoparticles triggered by local myeloperoxidase and reactive oxygen species. By combining a cyclodextrin-derived bioactive material with Tyr decoration, a multifunctional nanotherapy (TTN) was further developed, which displayed enhanced cellular uptake, anti-inflammatory activities, and inflammatory tissue accumulation, thereby affording amplified therapeutic effects in mice with colitis or acute liver injury. Moreover, TTN can serve as a bioactive and inflammation-targeting nanoplatform for site-specifically delivering a therapeutic peptide to the inflamed colon post oral administration, leading to considerably potentiated in vivo efficacies. Preliminary studies also revealed good safety of orally delivered TTN. Consequently, Tyr-based functionalization is promising for inflammation targeting amplification and therapeutic potentiation of nanotherapies.
Rates of laboratory adverse events by course in paediatric leukaemia ascertained with automated electronic health record extraction: a retrospective cohort study from the Children's Oncology Group
Authors: Tamara P Miller, Kelly D Getz, Yimei Li, Biniyam G Demissei, Peter C Adamson, Todd A Alonzo, Evanette Burrows, Lusha Cao, Sharon M Castellino, Marla H Daves, Brian T Fisher, Robert Gerbing, Robert W Grundmeier, Edward M Krause, Judy Lee, Philip J Lupo, Karen R Rabin, Mark Ramos, Michael E Scheurer, Jennifer J Wilkes, Lena E Winestone, Douglas S Hawkins, M Monica Gramatges, Richard Aplenc
Journal: The Lancet Haematology (2022)
From food price crisis to an equitable food system
Authors: Corinna Hawkes, Ramya Ambikapathi, Kim Anastasiou, Jessica Brock, Luciana Castronuovo, Naomi Fallon, Hazel Malapit, Assumpta Ndumi, Folake Samuel, Maryse Umugwaneza, Milkah N Wanjohi, Christina Zorbas
Journal: The Lancet (2022)
Immunological memory to common cold coronaviruses assessed longitudinally over a three-year period pre-COVID19 pandemic
Authors: Esther Dawen Yu, Tara M. Narowski, Eric Wang, Emily Garrigan, Jose Mateus, April Frazier, Daniela Weiskopf, Alba Grifoni, Lakshmanane Premkumar, Ricardo da Silva Antunes, Alessandro Sette
Journal: Cell Host & Microbe (2022)
Oncogenic collagen I homotrimers from cancer cells bind to α3β1 integrin and impact tumor microbiome and immunity to promote pancreatic cancer
Authors: Yang Chen, Sujuan Yang, Jena Tavormina, Desiree Tampe, Michael Zeisberg, Huamin Wang, Krishnan K. Mahadevan, Chang-Jiun Wu, Hikaru Sugimoto, Chia-Chi Chang, Robert R. Jenq, Kathleen M. McAndrews, Raghu Kalluri
Journal: Cancer Cell (2022)
Intrahepatic CD69<sup>+</sup>Vδ1 T cells re-circulate in the blood of patients with metastatic colorectal cancer and limit tumor progression
Authors: Elena Bruni, Matteo Maria Cimino, Matteo Donadon, Roberta Carriero, Sara Terzoli, Rocco Piazza, Sarina Ravens, Immo Prinz, Valentina Cazzetta, Paolo Marzano, Paolo Kunderfranco, Clelia Peano, Cristiana Soldani, Barbara Franceschini, Federico Simone Colombo, Cecilia Garlanda, Alberto Mantovani, Guido Torzilli, Joanna Mikulak, Domenico Mavilio
Journal: Journal for ImmunoTherapy of Cancer (2022)

Background More than 50% of all patients with colorectal cancer (CRC) develop liver metastases (CLM), a clinical condition characterized by poor prognosis and lack of reliable prognostic markers. Vδ1 cells are a subset of tissue-resident gamma delta (γδ) T lymphocytes endowed with a broad array of antitumor functions and showing a natural high tropism for the liver. However, little is known about their impact in the clinical outcomes of CLM. Methods We isolated human γδ T cells from peripheral blood (PB) and peritumoral (PT) tissue of 93 patients undergone surgical procedures to remove CLM. The phenotype of freshly purified γδ T cells was assessed by multiparametric flow cytometry, the transcriptional profiles by single cell RNA-sequencing, the functional annotations by Gene Ontology enrichment analyses and the clonotype by γδ T cell receptor (TCR)-sequencing. Results The microenvironment of CLM is characterized by a heterogeneous immune infiltrate comprising different subsets of γδ tumor-infiltrating lymphocytes (TILs) able to egress the liver and re-circulate in PB. Vδ1 T cells represent the largest population of γδ TILs within the PT compartment of CLM that is greatly enriched in Vδ1 T effector (T EF ) cells expressing constitutive high levels of CD69. These Vδ1 CD69 + TILs express a distinct phenotype and transcriptional signature, show high antitumor potential and correlate with better patient clinical outcomes in terms of lower numbers of liver metastatic lesions and longer overall survival (OS). Moreover, intrahepatic CD69 + Vδ1 TILs can egress CLM tissue to re-circulate in PB, where they retain a phenotype, transcriptional signature and TCR clonal repertoires resembling their liver origin. Importantly, even the increased frequencies of the CD69 + terminally differentiated (T EMRA ) Vδ1 cells in PB of patients with CLM significantly correlate with longer OS. The positive prognostic score of high frequencies of CD69 + T EMRA Vδ1 cells in PB is independent from the neoadjuvant chemotherapy and immunotherapy regimens administered to patients with CLM prior surgery. Conclusions The enrichment of tissue-resident CD69 + Vδ1 T EMRA cells re-circulating at high frequencies in PB of patients with CLM limits tumor progression and represents a new important clinical tool to either predict the natural history of CLM or develop alternative therapeutic protocols of cellular therapies.
Targeted Delivery of DNA Topoisomerase Inhibitor SN38 to Intracranial Tumors of Glioblastoma Using Sub‐5 Ultrafine Iron Oxide Nanoparticles (Adv. Healthcare Mater. 14/2022)
Authors: Yuancheng Li, Manman Xie, Joshua B. Jones, Zhaobin Zhang, Zi Wang, Tu Dang, Xinyu Wang, Malgorzata Lipowska, Hui Mao
Journal: Advanced Healthcare Materials (2022)
Multiple molecular mechanisms are involved in the activation of the kidney sodium-chloride cotransporter by hypokalemia
Authors: Adrián R. Murillo-de-Ozores, Héctor Carbajal-Contreras, Germán R. Magaña-Ávila, Raquel Valdés, Leoneli I. Grajeda-Medina, Norma Vázquez, Teresa Zariñán, Alejandro López-Saavedra, Avika Sharma, Dao-Hong Lin, Wen-Hui Wang, Eric Delpire, David H. Ellison, Gerardo Gamba, María Castañeda-Bueno
Journal: Kidney International (2022)
Mobile Nanobots for Prevention of Root Canal Treatment Failure (Adv. Healthcare Mater. 14/2022)
Authors: Debayan Dasgupta, Shanmukh Peddi, Deepak Kumar Saini, Ambarish Ghosh
Journal: Advanced Healthcare Materials (2022)

Root Canal Treatment Root canal treatments fail due to remnant bacteria in the tubules of the dentine tissue of human teeth. In article number 2200232 by Ambarish Ghosh and co-workers, magnetic nanobots can target pathogens deep inside the dentine, thereby reducing the bacterial load and preventing the failure of root canal treatment. This technique can reduce the global burden of oral diseases.
Enhancement of anticancer immunity by immunomodulation of apoptotic tumor cells using annexin A5 protein-labeled nanocarrier system
Authors: Sung Eun Lee, Chan Mi Lee, Ji Eun Won, Gun-Young Jang, Ju Hyeong Lee, Sang Hyeon Park, Tae Heung Kang, Hee Dong Han, Yeong-Min Park
Journal: Biomaterials (2022)
Novel gold-platinum nanoparticles serve as broad-spectrum antioxidants for attenuating ischemia reperfusion injury of the kidney
Authors: Shijian Feng, Ying Qu, Bingyang Chu, Xiaoting Chen, Ziyan Yang, Peiwen Li, Peiyu Wang, Qiyu He, Yushi He, Tao Lin, Zhongli Huang, Zhiyong Qian
Journal: Kidney International (2022)
Therapeutic targeting of PD-1/PD-L1 blockade by novel small-molecule inhibitors recruits cytotoxic T cells into solid tumor microenvironment
Authors: Rita C. Acúrcio, Sabina Pozzi, Barbara Carreira, Marta Pojo, Nuria Gómez-Cebrián, Sandra Casimiro, Adelaide Fernandes, Andreia Barateiro, Vitor Farricha, Joaquim Brito, Ana Paula Leandro, Jorge A R Salvador, Luís Graça, Leonor Puchades-Carrasco, Luís Costa, Ronit Satchi-Fainaro, Rita C. Guedes, Helena F. Florindo
Journal: Journal for ImmunoTherapy of Cancer (2022)

Background Inhibiting programmed cell death protein 1 (PD-1) or PD-ligand 1 (PD-L1) has shown exciting clinical outcomes in diverse human cancers. So far, only monoclonal antibodies are approved as PD-1/PD-L1 inhibitors. While significant clinical outcomes are observed on patients who respond to these therapeutics, a large proportion of the patients do not benefit from the currently available immune checkpoint inhibitors, which strongly emphasize the importance of developing new immunotherapeutic agents. Methods In this study, we followed a transdisciplinary approach to discover novel small molecules that can modulate PD-1/PD-L1 interaction. To that end, we employed in silico analyses combined with in vitro , ex vivo , and in vivo experimental studies to assess the ability of novel compounds to modulate PD-1/PD-L1 interaction and enhance T-cell function. Results Accordingly, in this study we report the identification of novel small molecules, which like anti-PD-L1/PD-1 antibodies, can stimulate human adaptive immune responses. Unlike these biological compounds, our newly-identified small molecules enabled an extensive infiltration of T lymphocytes into three-dimensional solid tumor models, and the recruitment of cytotoxic T lymphocytes to the tumor microenvironment in vivo , unveiling a unique potential to transform cancer immunotherapy. Conclusions We identified a new promising family of small-molecule candidates that regulate the PD-L1/PD-1 signaling pathway, promoting an extensive infiltration of effector CD8 T cells to the tumor microenvironment.
Errors in Byline and Affiliations
Authors: Chana Weinstock, Anup Amatya, Julia Beaver
Journal: JAMA Oncology (2022)

Qamar J. Khan, MD; Cory R. Bivona, PharmD; Grace A. Martin, PharmD; Jun Zhang, MD, PhD; Ben Liu, MS; Jianghua He, PhD; Kevin H. Li, BA; Maggie Nelson, PharmD; Stephen Williamson, MD; Gary C. Doolittle, MD; Weijing Sun, MD; Dinesh Pal Mudaranthakam, MBA; Natalie R. Streeter, BA, MSN; Joseph P. McGuirk, DO; Raed Al-Rajabi, MD; Marc Hoffmann, MD; Anup Kasi, MD, MPH; Rahul A. Parikh, MD; Cuncong Zhong, PhD; Laura Mitchell, BS; Ziyan Y. Pessetto, PhD; Harsh Pathak, PhD; Arnab Ghosh, PhD; Stephanie LaFaver, MSN; Priyanka Sharma, MD; Andrew K. Godwin, PhD
Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood
Authors: Jennifer Wilkinson Carlisle, Caroline S Jansen, Maria Andrea Cardenas, Ewelina Sobierajska, Adriana Moon Reyes, Rachel Greenwald, Luke Del Balzo, Nataliya Prokhnevska, Omer Kucuk, Bradley C Carthon, Patrick Connor Mullane, Adeboye Osunkoya, Deborah Baumgarten, Fares Hosseinzadeh, Scott Wilkinson, Ross Lake, Adam G Sowalsky, Yuan Liu, Viraj A Master, Mehmet A Bilen, Haydn Kissick
Journal: Journal for ImmunoTherapy of Cancer (2022)

Purpose Checkpoint therapy is now the cornerstone of treatment for patients with renal cell carcinoma (RCC) with advanced disease, but biomarkers are lacking to predict which patients will benefit. This study proposes potential immunological biomarkers that could developed for predicting therapeutic response in patients with RCC. Methods Using flow cytometry, RNA sequencing, and T-cell receptor (TCR) sequencing, we investigated changes in T cells in the peripheral blood of patients with advanced RCC after receiving immunotherapy. We used immunofluorescence (IF) imaging and flow cytometry to investigate how intratumoral T cells in patients’ tumors (resected months/years prior to receiving checkpoint therapy) predicted patient outcomes after immunotherapy. Results We found that a small proportion of CD4 and CD8 T cells in the blood activate following checkpoint therapy, expressing the proliferation marker Ki67 and activation markers HLA-DR and CD38. Patients who had the highest increase in these HLA-DR +CD38+CD8 T cells after treatment had the best antitumor immune response and experienced clinical benefit. Using RNA sequencing, we found that while these cells expanded in most patients, their phenotype did not drastically change during treatment. However, when we analyzed the TCR repertoire of these HLA-DR +CD38+CD8+T cells, we found that only patients who clinically benefitted had a burst of new clonotypes enter this pool of activated cells. Finally, we found that abundant T cells in the untreated tumors predicted clinical benefit to checkpoint therapy on disease progression. Conclusions Together, these data suggest that having a strong pre-existing immune response and immediate peripheral T-cell activation after checkpoint therapy is a predictor of clinical benefit in patients with RCC.
Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects
Authors: Solange Peters, Luis Paz-Ares, Roy S Herbst, Martin Reck
Journal: Journal for ImmunoTherapy of Cancer (2022)

Lung cancer remains a leading cause of cancer death worldwide, with non-small-cell lung cancer (NSCLC) accounting for the majority of cases. Immune checkpoint inhibitors (CPIs), including those targeting programmed cell death protein-1 and its ligand (PD-1/PD-L1), have revolutionized the treatment landscape for various cancers. Notably, PD-1/PD-L1 inhibitor-based regimens now form the standard first-line therapy for metastatic NSCLC, substantially improving patients' overall survival. Despite the progress made using CPI-based therapies in advanced NSCLC, most patients experience disease progression after an initial response due to resistance. Given the currently limited therapeutic options available for second-line and beyond settings in NSCLC, new treatment approaches are needed to improve long-term survival in these patients. Thus, CPI resistance is an emerging concept in cancer treatment and an active area of clinical research.Among the key mechanisms of CPI resistance is the immunosuppressive tumor microenvironment (TME). Effective CPI therapy is based on shifting immune responses against cancer cells, therefore, manipulating the immunosuppressive TME comprises an important strategy to combat CPI resistance. Several aspects of the TME can contribute to treatment resistance in NSCLC, including through the activation of Tyro3, Axl, MerTK (TAM) receptors which are essential pleiotropic regulators of immune homeostasis. Their roles include negatively modulating the immune response, therefore ectopic expression of TAM receptors in the context of cancer can contribute to the immunosuppressive, protumorigenic TME. Furthermore, TAM receptors represent important candidates to simultaneously target both tumor cells and immune cells in the TME. Clinical development of TAM receptor inhibitors (TAM RIs) is increasingly focused on their ability to rescue the antitumor immune response, thereby shifting the immunosuppressive TME to an immunostimulatory TME. There is a strong biological rationale for combining TAM RIs with a CPI to overcome resistance and improve long-term clinical responses in NSCLC. Combinatorial clinical trials of TAM RIs with CPIs are underway with encouraging preliminary results. This review outlines the key mechanisms of CPI resistance, including the role of the immunosuppressive TME, and discusses the rationale for targeting TAM receptors as a novel, promising therapeutic strategy to overcome CPI resistance in NSCLC.
Management of difficult hepatic artery reconstructions to reduce complications through continual technical refinements in living donor liver transplantations
Authors: Tsan-Shiun Lin, Cen-Hung Lin, Pao-Jen Kuo, Johnson Chia-Shen Yang, Yuan-Cheng Chiang, Wei-Feng Li, Shih-Ho Wang, Chih-Che Lin, Yueh-Wei Liu, Chee-Chien Yong, Chao-Long Chen, Yu-Fan Cheng, Chih-Chi Wang
Journal: International Journal of Surgery (2022)

Hepatic artery reconstruction (HAR) for liver transplantation is crucial for successful outcomes. We evaluated transplantation outcome improvement through continual technical refinements. HAR was performed in 1448 living donor liver transplants by a single plastic surgeon from 2008 to 2020. Difficult HARs were defined as graft or recipient hepatic artery ≤2 mm, size discrepancy (≥2 to 1), multiple hepatic arteries, suboptimal quality, intimal dissection of graft or recipient hepatic artery (HA), and immediate redo during transplantation. Technique refinements include early vessel injury recognition, precise HA dissection, the use of clips to ligate branches, an oblique cut for all HARs, a modified funneling method for size discrepancy, liberal use of an alternative artery to replace a pathologic HA, and reconstruction of a second HA for grafts with dual hepatic arteries in the graft. Difficult HARs were small HA (21.35%), size discrepancy (12.57%), multiple hepatic arteries (11.28%), suboptimal quality (31.1%), intimal dissection (20.5%), and immediate redo (5.18%). The overall hepatic artery thrombosis (HAT) rate was 3.04% in this series. The average HAT rate during the last 4 years (2017–2020) was 1.46% (6/408), which was significantly lower than the average HAT rate from 2008 to 2016 (39/1040, 3.8%) with a statistical significance (p = 0.025). Treatment for posttransplant HAT included anastomosis after trim back (9), reconstruction using alternatives (19), and nonsurgical treatment with urokinase (9). Careful examination of the HA under surgical microscope and selection of the appropriate recipient HA are key to successful reconstruction. Through continual technical refinements, we can reduce HA complications to the lowest degree.
Stress Relaxation and Composition of Hydrazone‐Crosslinked Hybrid Biopolymer‐Synthetic Hydrogels Determine Spreading and Secretory Properties of MSCs (Adv. Healthcare Mater. 14/2022)
Authors: Alexandra N. Borelli, Mark W. Young, Bruce E. Kirkpatrick, Matthew W. Jaeschke, Sarah Mellett, Seth Porter, Michael R. Blatchley, Varsha V. Rao, Balaji V. Sridhar, Kristi S. Anseth
Journal: Advanced Healthcare Materials (2022)
Multimodule characterization of immune subgroups in intrahepatic cholangiocarcinoma reveals distinct therapeutic vulnerabilities
Authors: Jian Lin, Yuting Dai, Chen Sang, Guohe Song, Bin Xiang, Mao Zhang, Liangqing Dong, Xiaoli Xia, Jiaqiang Ma, Xia Shen, Shuyi Ji, Shu Zhang, Mingjie Wang, Hai Fang, Xiaoming Zhang, Xiangdong Wang, Bing Zhang, Jian Zhou, Jia Fan, Hu Zhou, Daming Gao, Qiang Gao
Journal: Journal for ImmunoTherapy of Cancer (2022)

Background Immune microenvironment is well recognized as a critical regulator across cancer types, despite its complex roles in different disease conditions. Intrahepatic cholangiocarcinoma (iCCA) is characterized by a tumor-reactive milieu, emphasizing a deep insight into its immunogenomic profile to provide prognostic and therapeutic implications. Methods We performed genomic, transcriptomic, and proteomic characterization of 255 paired iCCA and adjacent liver tissues. We validated our findings through H&amp;E staining (n=177), multiplex immunostaining (n=188), single-cell RNA sequencing (scRNA-seq) (n=10), in vitro functional studies, and in vivo transposon-based mouse models. Results Integrated multimodule data identified three immune subgroups with distinct clinical, genetic, and molecular features, designated as IG1 (immune-suppressive, 25.1%), IG2 (immune-exclusion, 42.7%), and IG3 (immune-activated, 32.2%). IG1 was characterized by excessive infiltration of neutrophils and immature dendritic cells (DCs). The hallmark of IG2 was the relatively higher tumor-proliferative activity and tumor purity. IG3 exhibited an enrichment of adaptive immune cells, natural killer cells, and activated DCs. These immune subgroups were significantly associated with prognosis and validated in two independent cohorts. Tumors with KRAS mutations were enriched in IG1 and associated with myeloid inflammation-dominated immunosuppression. Although tumor mutation burden was relatively higher in IG2, loss of heterozygosity in human leucocyte antigen and defects in antigen presentation undermined the recognition of neoantigens, contributing to immune-exclusion behavior. Pathological analysis confirmed that tumor-infiltrating lymphocytes and tertiary lymphoid structures were both predominant in IG3. Hepatitis B virus (HBV)-related samples tended to be under-represented in IG1, and scRNA-seq analyses implied that HBV infection indeed alleviated myeloid inflammation and reinvigorated antitumor immunity. Conclusions Our study elucidates that the immunogenomic traits of iCCA are intrinsically heterogeneous among patients, posing great challenge and opportunity for the application of personalized immunotherapy.
O12-1 Ramucirumab-containing chemotherapy for gastrointestinal neuroendocrine carcinoma: RAM-NEC study (WJOG13420G)
Authors: Yuki Matsubara, Toshiki Masuishi, Hidekazu Hirano, Saori Mishima, Mitsuhiro Furuta, Tomoyuki Otsuka, Kenta Kawasaki, Takeshi Kawakami, Kazuhiro Yanagihara, Takaya Shimura, Masato Komoda, Kozue Murayama, Keiko Minashi, Yoshiyuki Yamamoto, Yudai Shinohara, Shinichi Nishina, Nobuyuki Musha, Kyoko Kato, Isao Oze, Kei Muro
Journal: Annals of Oncology (2022)
MO41-5 PD-L1 promoter methylation predicts survival in advanced colorectal cancer patients who received preoperative CCRT
Authors: Kevin Chih-Yang Huang, Kun-San Clifford Chao, Shu-Fen Chiang, Tao-Wei Ke, William Tzu-Liang Chen, Pei-Chen Yang, Tsung-Wei Chen
Journal: Annals of Oncology (2022)